CymaBay Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
NEWARK, CA -- (Marketwired) -- 07/28/14 -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) announced today the closing of its public offering of 4,600,000 shares of common stock at a public offering price of $5.50 per share. This includes the exercise in full by the underwriters of their option to purchase up to 600,000 additional shares of common stock at the same price. The net proceeds from the sale of the shares, after deducting the underwriters' discounts and other estimated offering expense payable by CymaBay Therapeutics will be approximately $22.8 million.
Cowen and Company and Stifel acted as the joint book-running managers, Roth Capital Partners and National Securities Corporation acted as co-managers for the offering.
A registration statement relating to the securities sold in this offering was declared effective on July 21, 2014. The offering was made only by means of a written prospectus forming part of the effective registration statement. Copies of the final prospectus may be obtained on the SEC EDGAR Filings Website: http://www.sec.gov/, or from Cowen and Company, LLC, (c/o Broadridge Financial Services., 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, Phone: 631-274-2806, Fax: 631-254-7140), or Stifel, Nicolaus & Company, Incorporated Attention: Prospectus Dept., One Montgomery Street, Suite 3700, San Francisco, California 94104, Phone: 415-364-2500 or by email at syndprospectus@stifel.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About CymaBay Therapeutics, Inc.
CymaBay Therapeutics, Inc. is focused on developing therapies to treat serious rare and orphan metabolic diseases or more prevalent diseases with high unmet medical need.
For additional information about CymaBay visit www.cymabay.com.
Contact:
Sujal Shah
CymaBay Therapeutics, Inc.
(510) 293-8800
investors@cymabay.com
Adam Cutler
The Trout Group, LLC
(646) 378-2936
CymaBay@troutgroup.com
Source: CymaBay Therapeutics
Released July 28, 2014